Jump to Main Content
Application of high-speed counter-current chromatography coupled with a reverse micelle solvent system to separate three proteins from Momordica charantia
- Li, Yingnan, Yin, Lianhong, Zheng, Lingli, Xu, Lina, Xu, Youwei, Zhao, Yanyan, Qi, Yan, Yao, Jihong, Han, Xu, Liu, Kexin, Peng, Jinyong
- Journal of chromatography 2012 v.895-896 pp. 77-82
- Momordica charantia, antineoplastic agents, countercurrent chromatography, databases, humans, in vitro studies, iso-octanes, micelles, pH, polyacrylamide gel electrophoresis, potassium chloride, proteins, sodium dodecyl sulfate, solvents, stomach neoplasms, temperature, wavelengths
- High-speed counter-current chromatography (HSCCC) coupled with a reverse micelle solvent system was successfully developed to separate three proteins from Momordica charantia. Suitable HSCCC conditions were carefully optimized as follows: the stationary phase was a reverse micellar phase composed of isooctane and 50mM bis-(2-ethylhexyl)-1-sulfosuccinate sodium (AOT). The mobile phase contained mobile phase A (50mM Tris–HCl buffer containing 50mM KCl at pH 7.0) for forward-extraction and mobile phase B (50mM Tris–HCl buffer containing 0.5M KCl at pH 10.0) for back-extraction. The flow rate, detection wavelength and column temperature were set at 1.5ml/min, 280nm and 4°C, respectively. Under these conditions, three fractions (I, II and III) were separated, which showed high purity when analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The structures of these proteins were then identified by MALDI-TOF/TOF-MS/MS and compared with the NCBInr database. Fractions I and III were identified as resistance-like protein P-B and pentatricopeptide repeat-containing protein, respectively, which were found in M. charantia for the first time. However, fraction II, which is thought to be a new protein, was not identified, and further investigations on this fraction are required. The anticancer activities of these three proteins on the human gastric cancer cell line SGC-7901 were evaluated in vitro. The results indicated that fraction II has excellent anticancer activity (IC₅₀=0.116mg/ml for 48h treatment). This is the first report on the use of HSCCC to isolate proteins from M. charantia.